{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T18:40:29Z","timestamp":1770489629057,"version":"3.49.0"},"reference-count":19,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T00:00:00Z","timestamp":1536537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Brentuximab vedotin (Bv) is becoming increasingly important in the treatment of Hodgkin lymphoma (<jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content>), with improved outcomes and an overall favourable toxicity profile. However, Bv is associated with severe pulmonary toxicity when combined with bleomycin, suggesting that additive toxicity may be an important consideration. Furthermore, little has been published on tolerability in paediatric patients. We retrospectively evaluated the occurrence of pulmonary toxicity of Bv in 19 paediatric and young adult patients with relapsed or refractory <jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content>. Patient characteristics, baseline health status, treatment regimens including cumulative doses of Bv, bleomycin, gemcitabine, radiation and carmustine, and the occurrence of pulmonary toxicity were collected. Seven (36\u00b78%) of the 19 patients were treated with Bv. The odds of pulmonary toxicity were 4\u00b70\u2010fold higher (95% confidence interval 0\u00b755\u201329\u00b718) in patients exposed to Bv compared to unexposed patients in univariate analysis (<jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b717). Similar results were found in multivariable analysis. Pulmonary toxicity occurred frequently in our cohort and was more common in patients who received Bv than in patients who did not receive Bv, although this was not statistically significant. Because patients with <jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content> are exposed to a myriad of therapies with potential for pulmonary toxicity, continuing to evaluate the risk associated with Bv is critical.<\/jats:p>","DOI":"10.1111\/bjh.15586","type":"journal-article","created":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T11:48:45Z","timestamp":1536580125000},"page":"251-256","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pulmonary toxicity in paediatric patients with relapsed or refractory Hodgkin lymphoma receiving brentuximab vedotin"],"prefix":"10.1111","volume":"183","author":[{"given":"Kelly E.","family":"Faulk","sequence":"first","affiliation":[{"name":"Center for Cancer and Blood Disorders Department of Paediatrics University of Colorado School of Medicine Aurora CO USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5191-7511","authenticated-orcid":false,"given":"Jenna M.","family":"Sopfe","sequence":"additional","affiliation":[{"name":"Center for Cancer and Blood Disorders Department of Paediatrics University of Colorado School of Medicine Aurora CO USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Paediatrics University of Colorado School of Medicine Aurora CO USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah R.","family":"Liptzin","sequence":"additional","affiliation":[{"name":"Paediatric Respiratory Center Department of Paediatrics University of Colorado School of Medicine Aurora CO USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur K.","family":"Liu","sequence":"additional","affiliation":[{"name":"Center for Cancer and Blood Disorders Department of Paediatrics University of Colorado School of Medicine Aurora CO USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna R. K.","family":"Franklin","sequence":"additional","affiliation":[{"name":"Center for Cancer and Blood Disorders Department of Paediatrics University of Colorado School of Medicine Aurora CO USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrye R.","family":"Cost","sequence":"additional","affiliation":[{"name":"Center for Cancer and Blood Disorders Department of Paediatrics University of Colorado School of Medicine Aurora CO USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,9,10]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1256481"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21808"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq211"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.09.114"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-278796"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.3109\/09513590.2013.852531"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-699850"},{"key":"e_1_2_7_9_1","volume-title":"Long\u2010Term Follow Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancer","author":"COG","year":"2013"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.7527"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708984"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11582"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-703470"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2438_111"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60165-9"},{"key":"e_1_2_7_16_1","unstructured":"NCCN. (2018)NCCN Guidelines\u00aefor Hodgkin Lymphoma V.3.2018. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology. \u00a9 National Comprehensive Cancer Network Inc. 2018. All rights reserved. Accessed April 16 2018. To view the most recent and complete version of the guideline go online to NCCN.org."},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.134213"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002965"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70501-1"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15586","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15586","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T12:46:39Z","timestamp":1694868399000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,10]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1111\/bjh.15586"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15586","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,10]]},"assertion":[{"value":"2018-09-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}